Table 2.
Study | Allelic frequencies*
|
Genotypic distribution*
|
Odds ratios with 95% confidence intervals
|
Stratification analysis | ||||||
---|---|---|---|---|---|---|---|---|---|---|
C allele | G allele | CC | GC | GG | C allele versus G allele | CC versus GG | GC + CC versus GG | CC versus GG + GC | ||
Poonpet et al6 | 214/192 | 186/208 | 56/46 | 102/100 | 42/52 | 1.25 (0.94–1.66) | 1.57 (0.86–2.85) | 1.34 (0.84–2.13) | 1.29 (0.82–2.02) | By gender |
Shin et al12 | 658/1,563 | 792/1,911 | 147/350 | 364/863 | 214/524 | 0.99 (0.87–1.14) | 1.01 (0.76–1.33) | 1.03 (0.85–1.25) | 1.01 (0.81–1.25) | By gender |
Kerna et al10 (TFOA part) | 44/88 | 22/35 | 28/65 | 32/46 | 6/12 | 1.28 (0.52–4.35) | 0.85 (0.29–2.49) | 0.54 (0.17–1.75) | 0.66 (0.36–1.20) | By gender |
Kerna et al10 (PFOA part) | 70/62 | 27/30 | 53/41 | 34/43 | 10/8 | 1.16 (0.75–1.82) | 1.01 (0.37–2.80) | 0.83 (0.31–2.20) | 1.50 (0.84–2.66) | By gender |
Rodriguez-Lopez et al11 (TKR part) | NG | NG | NG | NG | NG | 0.92 (0.81–1.05) | NG | NG | NG | By gender |
Rodriguez-Lopez et al11 (THR part) | NG | NG | NG | NG | NG | 1.08 (0.96–1.21) | NG | NG | NG | By gender |
Valdes et al9 | NG | NG | NG | NG | NG | NG | NG | 1.84 (1.22–2.79) | NG | None |
Wang et al5 | 47.6%/49.0% | 52.4%/51.0% | 36/47 | 84/102 | 44/51 | 0.93 (0.76–1.14) | 0.87 (0.48–1.61) | 0.92 (0.58–1.49) | 0.90 (0.54–1.52) | None |
Limer et al16 | NG | NG | NG | NG | NG | 1.01 (0.90–1.13) | NG | NG | NG | By hip and knee OA |
Lou et al4 | 46.7%/49.4% | 53.3%/50.6% | 32/42 | 78/93 | 42/44 | 0.89 (0.65–1.22) | 0.79 (0.41–1.50) | 0.88 (0.53–1.46) | 0.87 (0.52–1.47) | None |
Note:
Data are presented as case number/control number or case percentage/control percentage.
Abbreviations: TKR, total knee replacement; THR, total hip replacement; TFOA, tibiofemoral knee OA; PFOA, patellofemoral knee OA; NG, not given; OA, osteoarthritis.